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gies for this antibiotic in order to maximize clinical efﬁcacy,
reduce patient risk of developing bacterial resistance and
minimize adverse effects.
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Intravaginal pentamycin for the treatment of bacterial
vaginosis
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1 Lumavita AG, Basel, Switzerland
2 Gynäkologie und Geburtshilfe, Spiez, Switzerland
Background: Pentamycin 3mg vaginal tablets
(FemiFect®, Lumavita AG, Basel, Switzerland) is effective
in the treatment of vaginal infections caused by Tri-
chomonas vaginalis, Candida albicans and mixed ﬂora (Clin.
Ter. 92: 137-142, 1980; Internet Journal of Gynecology
and Obstetrics 11(1), 2009). While pentamycin has shown
in-vitro activity against some pathogenic bacteria, it is
inactive against the lactobacilli that colonize the healthy
vagina, making it an ideal therapeutic candidate for the
treatment of bacterial vaginoses. The objective of this
study was to investigate the efﬁcacy, safety and tolerability
of intravaginal pentamycin in women with symptomatic
bacterial vaginosis.
Methods: This open-label clinical trial included 92
women, aged 15-78 years, who attended the gynaecol-
ogy clinic for symptoms of vaginitis and had a diagnosis
of bacterial vaginosis on the basis of the history, com-
plete gynaecological examination, wet mount evaluation
and microbiological analysis. The causative agent was pri-
marily Gardnerella vaginalis in 43 patients, while diverse
bacteria were found in the vaginal secretions of the other
49 women.
Twenty-ﬁve patients had previously received other
antimicrobial therapies without beneﬁt. Patients were
treated with intravaginal pentamycin (6mg daily for 5 days,
n = 58; 3mg daily for up to 10 days, n = 34), either alone
(73.9% of cases) or in combination with other therapies.
The gynaecological examination and microbiological anal-
ysis were repeated at the end of the treatment period,
when the occurrence of systemic or local adverse events
was also recorded and patient’s satisfaction was assessed
by using a questionnaire. Efﬁcacy endpoints were resolution
of symptoms and eradication of the causative agents.
Results: Resolution of symptoms and eradication of the
causative agents were demonstrated in 74.4% and 69.8%,
respectively, of patients with bacterial vaginoses primarily
caused by G. vaginalis and in 87.8% and 75.5%, respectively,
of patients with bacterial vaginoses caused by diverse bac-
teria. Irrespective of the dose of pentamycin administered,
treatment acceptance was rated as ‘‘good’’ by 69.8% of
patients with bacterial vaginoses primarily sustained by G.
vaginalis and 79.6% of those with a disease caused by diverse
bacteria. The therapeutic regimen was well-tolerated in all
cases.
Conclusion: Intravaginal pentamycin, either alone or in
combination with other therapies, is effective in the treat-
ment of bacterial vaginoses. The drug exhibits a favourable
tolerability proﬁle and is well-accepted by patients.
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ntravenous colistin therapy for infections caused by
ultidrug-resistant gram-negative bacteria in critically ill
atients
. Cusato
Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
Background: The increasing incidence of infections
aused by multidrug-resistant (MDR) Pseudomonas aerugi-
osa, Acinetobacter baumannii and Klebsiella pneumoniae
s a worldwide problem, particularly among patients with
mmune deﬁciency, burns or neutropenia. The signiﬁcant
esistance of these bacteria to the commonly used antibi-
tics and the expected lack of new agents available in the
ear future lead the clinicians to test the efﬁcacy and safety
f colistin, an old antibiotic whose use decreased because
f suspected toxicity and which is now used as the last ther-
peutic resort.
Methods: Thirteen (10 M, 3F; mean [SD] age 45.3
18.3] years; mean [SD] estimated body weight, 82.8 [21.9]
g;) critically ill patients with different conditions were
nrolled. SAPS II and SOFA scores were used to predict mor-
ality in the intensive care unit. All patients were treated
ith colistin sulphomethate sodium (CMS) intravenously (2M
.U.) every 8 h. After at least three days of therapy, blood
amples were collected before and at 1,2,3,4,6,8 h after the
nd of the 30-minute IV infusion. Colistin was measured
ith a speciﬁc high-performance liquid chromatography
ethod. Pharmacokinetic parameters were determined by
oncompartmental analysis using the Kinetica InnaphaseTM
.0 software.
Results: Patients received 2.19± 0.38mg/kg (range 1.58-
.49) of CMS per dose. At the steady-state, plasma
olistin had a mean [± S.D.] AUC (0-8 h), Cthrough,
max, t½, CrCL of 11.54± 6.20g h/ml, 1.02± 0.69g/ml,
.21± 1.08g/ml, 5.87± 2.56 h and 142.9± 57.8mL/min,
espectively. A clinical response was observed in 92% of
atients; treatment failed in one patient with severe
nderlying conditions (cerebral cancer, pneumonia). The
ntibacterial effect of colistin was evaluated by the
max/MIC and AUC/MIC ratios; ratios differed according to
he considered bacteria.
Conclusion: Based on our pharmacokinetic results, the
aximum concentrations of colistin achieved were proba-
ly sufﬁcient to ensure optimal Cmax/MIC ratios for all the
ramnegative bacteria under study.
However, we need to redeﬁne appropriate dosing strate-
